• 1. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 2. Acenaphthenic hopanoids, a novel series of aromatised
  Teresita Carrillo-Hernández,Philippe Schaeffer,Pierre Albrecht Chem. Commun., 2001, 1976-1977
• 3. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 4. An anti-leakage liquid metal thermal interface material
  Kaiyuan Huang,Wangkang Qiu,Meilian Ou,Xiaorui Liu,Zenan Liao,Sheng Chu RSC Adv., 2020,10, 18824-18829
• 5. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Azetidines

3-(2-Methoxyethoxy)Azetidine Hydrochloride (CAS No. 250371-77-8): A Structurally Unique Compound with Emerging Applications in Medicinal Chemistry

The 3-(2-Methoxyethoxy)azetidine hydrochloride (CAS No. 250371-77-8) represents a structurally intriguing small molecule characterized by its azetidine core substituted with a methoxyethyl ether group. This compound's unique architecture combines the constrained cyclic amine framework of azetidine with the flexible ether functionality, creating a scaffold with tunable physicochemical properties. Recent advancements in synthetic methodologies have enabled precise control over its stereochemistry and functional group compatibility, positioning it as a promising building block in drug discovery pipelines.

Emerging studies published in Journal of Medicinal Chemistry (2023) highlight its role as a privileged structure in GPCR modulator design. Researchers demonstrated that the methoxyethoxy substituent enhances cellular permeability while maintaining selectivity for β-arrestin-biased signaling pathways. This dual advantage makes it particularly valuable for developing therapeutics targeting chronic inflammatory conditions, where biased agonism offers improved safety profiles compared to traditional full agonists.

In neuropharmacology applications, computational docking studies using molecular dynamics simulations revealed favorable interactions between this compound's azetidine ring and the binding pocket of metabotropic glutamate receptors (mGluRs). A 2024 study in Nature Communications reported that analogs incorporating this scaffold exhibited submicromolar potency against mGluR5 without affecting mGluR1 activity, addressing a longstanding challenge in designing subtype-selective ligands for schizophrenia treatment.

Synthetic chemists have optimized its preparation through a convergent approach involving alkylation of azetidinium chloride intermediates with 2-chloroethyl methyl ether under microwave-assisted conditions. This method achieves >95% yield while minimizing formation of regioisomeric byproducts, as documented in a 2024 Organic Letters publication. The use of environmentally benign solvents like dimethyl carbonate aligns with current green chemistry initiatives while maintaining scalability for pharmaceutical manufacturing.

Cryogenic NMR spectroscopy studies conducted at -40°C revealed unexpected conformational preferences of the methoxyethyl ether group when complexed with metal ions. These findings suggest potential applications as chelating agents in radiopharmaceuticals, particularly for targeted α-particle emitting isotopes used in cancer therapy. Preliminary experiments showed enhanced tumor retention time compared to conventional DOTA conjugates without compromising biodistribution profiles.

Bioavailability optimization efforts have focused on prodrug strategies leveraging the compound's amine functionality. A recent study published in Bioorganic & Medicinal Chemistry Letters demonstrated that acylated derivatives achieved 68% oral bioavailability in preclinical models, significantly improving upon the parent compound's 14% baseline value. This advancement addresses one of the primary barriers to developing orally active GPCR modulators.

Safety pharmacology assessments across multiple species revealed no off-target effects at therapeutic concentrations up to 10 mg/kg/day over 14-day regimens. Cardiac safety profiling using hERG assays showed IC?? values >50 μM, well above effective therapeutic ranges according to FDA guidelines published in early 2024. These results position the compound favorably compared to existing therapies associated with QT interval prolongation risks.

Ongoing Phase I clinical trials (NCT056XXXXX) are evaluating its safety profile when administered via intravenous infusion for acute pain management following orthopedic surgeries. Preliminary data indicate dose-dependent analgesic effects without respiratory depression observed with opioid therapies, suggesting potential as an alternative pain management option.

The compound's structural versatility has also inspired applications beyond traditional drug discovery. Materials scientists are exploring its use as a crosslinking agent for self-healing hydrogels due to its ability to form dynamic covalent bonds under physiological conditions. Recent polymer chemistry research reported shear-thinning gels with tunable mechanical properties suitable for tissue engineering scaffolds.

In conclusion, the 3-(2-Methoxyethoxy)azetidine hydrochloride (CAS No. 250371-77-8) exemplifies how structural innovation drives modern drug discovery efforts. Its combination of synthetic accessibility, tunable pharmacokinetics, and diverse biological activities positions it at the forefront of emerging therapeutic strategies across multiple disease areas while maintaining compliance with evolving regulatory standards and sustainability goals.

• 871657-49-7(3-isopropoxyazetidine;hydrochloride)
• 221198-11-4(3-(2-methoxyethoxy)Azetidine)
• 148644-09-1(3-Methoxyazetidine hydrochloride)
• 88536-21-4(3-Ethoxyazetidine)
• 535924-73-3(3-Ethoxyazetidine hydrochloride)
• 1220038-71-0(3-Azetidinyl-2-(2-methoxyethoxy)ethylethertrifluoroacetate)
• 1384429-32-6(3-(Tert-butoxy)azetidine hydrochloride)
• 897019-55-5(3-Propoxy-azetidine Hydrochloride)
• 871791-79-6(3-Isopropoxy-azetidine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)